Location matters: Overlooked ethnic‐geographic effect in China and Austria on propofol/cisatracurium sex differences among a population pharmacokinetic/pharmacodynamic (PopPK/PD) covariate analysis in men, women, and one transgender subject
A quick literature search using “sex/gender” vs. the commonly used hypnotic propofol or neuromuscular‐blocking agent cisatracurium will reveal numerous contradictory sex difference publications depending on the ethnic‐geographic location of where these studies were conducted. We induced anesthesia w...
Saved in:
Published in | Fundamental & clinical pharmacology Vol. 36; no. 1; pp. 182 - 198 |
---|---|
Main Authors | , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
England
Wiley Subscription Services, Inc
01.02.2022
|
Subjects | |
Online Access | Get full text |
ISSN | 0767-3981 1472-8206 1472-8206 |
DOI | 10.1111/fcp.12704 |
Cover
Loading…
Abstract | A quick literature search using “sex/gender” vs. the commonly used hypnotic propofol or neuromuscular‐blocking agent cisatracurium will reveal numerous contradictory sex difference publications depending on the ethnic‐geographic location of where these studies were conducted. We induced anesthesia with cisatracurium besylate (GlaxoSmithKline) 100 μg kg−1 administered exactly 1 minute following propofol (AstraZeneca) 2 mg kg−1. In 20 male and 20 female ethnic Han‐Chinese test set patients (Xi'an China), and in similar ethnic white Austrian validation set patients (Graz Austria), we quantified propofol/cisatracurium pharmacodynamic parameters namely propofol onset time, lag time, plasma concentrations (Cp) at loss‐of‐behavioral response (LOBR) using bispectral index (BIS); cisatracurium onset time, lag time, and Cp at T1% (first twitch of train‐of‐four) complete twitch suppression using mechanomyography (MMG). Serial arterial blood samples were collected for population pharmacokinetic (PopPK) analysis of all demographic and biological covariates (region, sex, age, weight, and height) versus volumes of distribution and clearances pharmacokinetic parameters. In Chinese women (but not in white women), propofol Cp at LOBR was 33.60% lower than men and cisatracurium Cp at T1% complete twitch suppression was 21.49% lower than men, a clear pharmacodynamic assertion. Region and weight were significant PopPK covariates. We demonstrated that sex differences are influenced by ethnic‐geographic location as only in Chinese women (but not in white women) propofol Cp at LOBR and cisatracurium Cp at T1% complete twitch suppression were lower than in men. When defining sex differences, ethnic‐geographic location should be taken into consideration as a predictive factor for optimizing propofol/cisatracurium initial loading recommended dosages. |
---|---|
AbstractList | A quick literature search using “sex/gender” vs. the commonly used hypnotic propofol or neuromuscular‐blocking agent cisatracurium will reveal numerous contradictory sex difference publications depending on the ethnic‐geographic location of where these studies were conducted. We induced anesthesia with cisatracurium besylate (GlaxoSmithKline) 100 μg kg−1 administered exactly 1 minute following propofol (AstraZeneca) 2 mg kg−1. In 20 male and 20 female ethnic Han‐Chinese test set patients (Xi'an China), and in similar ethnic white Austrian validation set patients (Graz Austria), we quantified propofol/cisatracurium pharmacodynamic parameters namely propofol onset time, lag time, plasma concentrations (Cp) at loss‐of‐behavioral response (LOBR) using bispectral index (BIS); cisatracurium onset time, lag time, and Cp at T1% (first twitch of train‐of‐four) complete twitch suppression using mechanomyography (MMG). Serial arterial blood samples were collected for population pharmacokinetic (PopPK) analysis of all demographic and biological covariates (region, sex, age, weight, and height) versus volumes of distribution and clearances pharmacokinetic parameters. In Chinese women (but not in white women), propofol Cp at LOBR was 33.60% lower than men and cisatracurium Cp at T1% complete twitch suppression was 21.49% lower than men, a clear pharmacodynamic assertion. Region and weight were significant PopPK covariates. We demonstrated that sex differences are influenced by ethnic‐geographic location as only in Chinese women (but not in white women) propofol Cp at LOBR and cisatracurium Cp at T1% complete twitch suppression were lower than in men. When defining sex differences, ethnic‐geographic location should be taken into consideration as a predictive factor for optimizing propofol/cisatracurium initial loading recommended dosages. A quick literature search using "sex/gender" vs. the commonly used hypnotic propofol or neuromuscular-blocking agent cisatracurium will reveal numerous contradictory sex difference publications depending on the ethnic-geographic location of where these studies were conducted. We induced anesthesia with cisatracurium besylate (GlaxoSmithKline) 100 μg kg-1 administered exactly 1 minute following propofol (AstraZeneca) 2 mg kg-1 . In 20 male and 20 female ethnic Han-Chinese test set patients (Xi'an China), and in similar ethnic white Austrian validation set patients (Graz Austria), we quantified propofol/cisatracurium pharmacodynamic parameters namely propofol onset time, lag time, plasma concentrations (Cp ) at loss-of-behavioral response (LOBR) using bispectral index (BIS); cisatracurium onset time, lag time, and Cp at T1 % (first twitch of train-of-four) complete twitch suppression using mechanomyography (MMG). Serial arterial blood samples were collected for population pharmacokinetic (PopPK) analysis of all demographic and biological covariates (region, sex, age, weight, and height) versus volumes of distribution and clearances pharmacokinetic parameters. In Chinese women (but not in white women), propofol Cp at LOBR was 33.60% lower than men and cisatracurium Cp at T1 % complete twitch suppression was 21.49% lower than men, a clear pharmacodynamic assertion. Region and weight were significant PopPK covariates. We demonstrated that sex differences are influenced by ethnic-geographic location as only in Chinese women (but not in white women) propofol Cp at LOBR and cisatracurium Cp at T1 % complete twitch suppression were lower than in men. When defining sex differences, ethnic-geographic location should be taken into consideration as a predictive factor for optimizing propofol/cisatracurium initial loading recommended dosages.A quick literature search using "sex/gender" vs. the commonly used hypnotic propofol or neuromuscular-blocking agent cisatracurium will reveal numerous contradictory sex difference publications depending on the ethnic-geographic location of where these studies were conducted. We induced anesthesia with cisatracurium besylate (GlaxoSmithKline) 100 μg kg-1 administered exactly 1 minute following propofol (AstraZeneca) 2 mg kg-1 . In 20 male and 20 female ethnic Han-Chinese test set patients (Xi'an China), and in similar ethnic white Austrian validation set patients (Graz Austria), we quantified propofol/cisatracurium pharmacodynamic parameters namely propofol onset time, lag time, plasma concentrations (Cp ) at loss-of-behavioral response (LOBR) using bispectral index (BIS); cisatracurium onset time, lag time, and Cp at T1 % (first twitch of train-of-four) complete twitch suppression using mechanomyography (MMG). Serial arterial blood samples were collected for population pharmacokinetic (PopPK) analysis of all demographic and biological covariates (region, sex, age, weight, and height) versus volumes of distribution and clearances pharmacokinetic parameters. In Chinese women (but not in white women), propofol Cp at LOBR was 33.60% lower than men and cisatracurium Cp at T1 % complete twitch suppression was 21.49% lower than men, a clear pharmacodynamic assertion. Region and weight were significant PopPK covariates. We demonstrated that sex differences are influenced by ethnic-geographic location as only in Chinese women (but not in white women) propofol Cp at LOBR and cisatracurium Cp at T1 % complete twitch suppression were lower than in men. When defining sex differences, ethnic-geographic location should be taken into consideration as a predictive factor for optimizing propofol/cisatracurium initial loading recommended dosages. A quick literature search using “sex/gender” vs. the commonly used hypnotic propofol or neuromuscular‐blocking agent cisatracurium will reveal numerous contradictory sex difference publications depending on the ethnic‐geographic location of where these studies were conducted. We induced anesthesia with cisatracurium besylate (GlaxoSmithKline) 100 μg kg−1 administered exactly 1 minute following propofol (AstraZeneca) 2 mg kg−1. In 20 male and 20 female ethnic Han‐Chinese test set patients (Xi'an China), and in similar ethnic white Austrian validation set patients (Graz Austria), we quantified propofol/cisatracurium pharmacodynamic parameters namely propofol onset time, lag time, plasma concentrations (Cp) at loss‐of‐behavioral response (LOBR) using bispectral index (BIS); cisatracurium onset time, lag time, and Cp at T1% (first twitch of train‐of‐four) complete twitch suppression using mechanomyography (MMG). Serial arterial blood samples were collected for population pharmacokinetic (PopPK) analysis of all demographic and biological covariates (region, sex, age, weight, and height) versus volumes of distribution and clearances pharmacokinetic parameters. In Chinese women (but not in white women), propofol Cp at LOBR was 33.60% lower than men and cisatracurium Cp at T1% complete twitch suppression was 21.49% lower than men, a clear pharmacodynamic assertion. Region and weight were significant PopPK covariates. We demonstrated that sex differences are influenced by ethnic‐geographic location as only in Chinese women (but not in white women) propofol Cp at LOBR and cisatracurium Cp at T1% complete twitch suppression were lower than in men. When defining sex differences, ethnic‐geographic location should be taken into consideration as a predictive factor for optimizing propofol/cisatracurium initial loading recommended dosages. A quick literature search using “sex/gender” vs. the commonly used hypnotic propofol or neuromuscular‐blocking agent cisatracurium will reveal numerous contradictory sex difference publications depending on the ethnic‐geographic location of where these studies were conducted. We induced anesthesia with cisatracurium besylate (GlaxoSmithKline) 100 μg kg −1 administered exactly 1 minute following propofol (AstraZeneca) 2 mg kg −1 . In 20 male and 20 female ethnic Han‐Chinese test set patients (Xi'an China), and in similar ethnic white Austrian validation set patients (Graz Austria), we quantified propofol/cisatracurium pharmacodynamic parameters namely propofol onset time, lag time, plasma concentrations (C p ) at loss‐of‐behavioral response (LOBR) using bispectral index (BIS); cisatracurium onset time, lag time, and C p at T 1 % (first twitch of train‐of‐four) complete twitch suppression using mechanomyography (MMG). Serial arterial blood samples were collected for population pharmacokinetic (PopPK) analysis of all demographic and biological covariates (region, sex, age, weight, and height) versus volumes of distribution and clearances pharmacokinetic parameters. In Chinese women (but not in white women), propofol C p at LOBR was 33.60% lower than men and cisatracurium C p at T 1 % complete twitch suppression was 21.49% lower than men, a clear pharmacodynamic assertion. Region and weight were significant PopPK covariates. We demonstrated that sex differences are influenced by ethnic‐geographic location as only in Chinese women (but not in white women) propofol C p at LOBR and cisatracurium C p at T 1 % complete twitch suppression were lower than in men. When defining sex differences, ethnic‐geographic location should be taken into consideration as a predictive factor for optimizing propofol/cisatracurium initial loading recommended dosages. A quick literature search using "sex/gender" vs. the commonly used hypnotic propofol or neuromuscular-blocking agent cisatracurium will reveal numerous contradictory sex difference publications depending on the ethnic-geographic location of where these studies were conducted. We induced anesthesia with cisatracurium besylate (GlaxoSmithKline) 100 μg kg administered exactly 1 minute following propofol (AstraZeneca) 2 mg kg . In 20 male and 20 female ethnic Han-Chinese test set patients (Xi'an China), and in similar ethnic white Austrian validation set patients (Graz Austria), we quantified propofol/cisatracurium pharmacodynamic parameters namely propofol onset time, lag time, plasma concentrations (C ) at loss-of-behavioral response (LOBR) using bispectral index (BIS); cisatracurium onset time, lag time, and C at T % (first twitch of train-of-four) complete twitch suppression using mechanomyography (MMG). Serial arterial blood samples were collected for population pharmacokinetic (PopPK) analysis of all demographic and biological covariates (region, sex, age, weight, and height) versus volumes of distribution and clearances pharmacokinetic parameters. In Chinese women (but not in white women), propofol C at LOBR was 33.60% lower than men and cisatracurium C at T % complete twitch suppression was 21.49% lower than men, a clear pharmacodynamic assertion. Region and weight were significant PopPK covariates. We demonstrated that sex differences are influenced by ethnic-geographic location as only in Chinese women (but not in white women) propofol C at LOBR and cisatracurium C at T % complete twitch suppression were lower than in men. When defining sex differences, ethnic-geographic location should be taken into consideration as a predictive factor for optimizing propofol/cisatracurium initial loading recommended dosages. |
Author | Dahaba, Ashraf A. Reibnegger, Gilbert Zelzer, Sieglinde Zhu, Xiaoling Dong, Hailong Xiong, Lize Xiao, Zhaoyang Oettl, Karl Zhao, Shuiyu |
Author_xml | – sequence: 1 givenname: Ashraf A. orcidid: 0000-0001-8513-3643 surname: Dahaba fullname: Dahaba, Ashraf A. email: ashraf.dahaba@medunigraz.at organization: Suez Canal University – sequence: 2 givenname: Zhaoyang surname: Xiao fullname: Xiao, Zhaoyang email: xiaozhaoy2012@163.com organization: Second Affiliated Hospital of Dalian Medical University – sequence: 3 givenname: Xiaoling surname: Zhu fullname: Zhu, Xiaoling organization: Xijing Hospital of Fourth Military Medical University – sequence: 4 givenname: Karl surname: Oettl fullname: Oettl, Karl organization: Medical University of Graz – sequence: 5 givenname: Hailong surname: Dong fullname: Dong, Hailong organization: Xijing Hospital of Fourth Military Medical University – sequence: 6 givenname: Lize surname: Xiong fullname: Xiong, Lize organization: Xijing Hospital of Fourth Military Medical University – sequence: 7 givenname: Sieglinde surname: Zelzer fullname: Zelzer, Sieglinde organization: Medical University of Graz – sequence: 8 givenname: Shuiyu surname: Zhao fullname: Zhao, Shuiyu organization: Shanghai Qiangshi Information Technology Co. Ltd – sequence: 9 givenname: Gilbert surname: Reibnegger fullname: Reibnegger, Gilbert organization: Medical University of Graz |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/34050969$$D View this record in MEDLINE/PubMed |
BookMark | eNp9ks1uEzEQxy1URNPCgRdAlri0EtvY--H1cqsCBUSk5gDn1cQ7mzjdtRfb25Ibj8Az8gg8AU7ScqgEvows_Wb-__k4IUfGGiTkJWcXPL5pq4YLnpYsf0ImPC_TRKZMHJEJK0WZZJXkx-TE-w1jvGRcPCPHWc4KVolqQn7PrYKgraE9hIDOv6XXt-g6a2-woRjWRqtfP36u0K4cDGutKLYtqkC1obO1NkDBNPRy9MFpoLHM4OxgW9tNlfYQHKjR6bGnHr_TRsdUh0ahp9Bbs6JABzuM3cHAsAbXg7I32mDQavrwb7YG-ih8trDD4vN08e6cKnsLUS9gVIdu67Xf-enRvKF3dh92ruKQaHRg_ApNg476cbmJ1p-Tpy10Hl_cx1Py9er9l9nHZH794dPscp6orMjyRBYCpawkVihFI1jLBV-yTIKUBeZNXiI2CE2-FDxL06LkomBQFkvMMi5UybNTcnaoG0fybUQf6l57hV0HBu3o6zSqCFZVoojo60foxo4uthYpwatcFlKwSL26p8Zlj009ON2D29YP24zA-QFQznrvsP2LcFbvLqWOl1LvLyWy00es0mG_iDgy3f0v4053uP136fpqtjhk_AFhetSC |
CitedBy_id | crossref_primary_10_1016_j_ejphar_2025_177429 crossref_primary_10_1093_sleep_zsac201 crossref_primary_10_1111_fcp_12732 crossref_primary_10_3390_jcm10204770 |
Cites_doi | 10.1093/bja/aeq040 10.1017/S026502150800402X 10.1007/BF01627635 10.1213/01.ANE.0000154534.71371.4F 10.2165/00003088-198106060-00002 10.1034/j.1399-6576.2003.00036.x 10.1097/00000542-199905000-00010 10.1093/bja/aer495 10.1097/00000542-199304000-00008 10.1111/j.1472-8206.2008.00642.x 10.1152/ajpregu.1998.275.6.R1909 10.1136/bmj.322.7288.710 10.1007/s40262-018-0672-3 10.1016/0166-2236(86)90158-X 10.1034/j.1399-6576.2000.440918.x 10.1111/j.1472-8206.2008.00647.x 10.1093/bja/aeg258 10.1111/j.1365-2044.2006.04548.x 10.1016/0010-4809(72)90051-1 10.1208/s12248-011-9255-z 10.1097/00000542-198210000-00012 10.1111/j.1472-8206.2011.01000.x 10.1016/S0378-4347(98)00576-3 10.1213/01.ane.0000223681.77120.ca 10.1023/A:1012015719694 10.1016/j.cmpb.2003.11.003 10.1111/j.1365-2125.2005.02393.x 10.1007/BF01061469 10.1373/49.1.7 10.1093/bja/aep143 |
ContentType | Journal Article |
Copyright | 2021 Société Française de Pharmacologie et de Thérapeutique 2021 Société Française de Pharmacologie et de Thérapeutique. 2022 John Wiley & Sons, Ltd. |
Copyright_xml | – notice: 2021 Société Française de Pharmacologie et de Thérapeutique – notice: 2021 Société Française de Pharmacologie et de Thérapeutique. – notice: 2022 John Wiley & Sons, Ltd. |
DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 7QL 7QO 7T7 7U7 7U9 8FD C1K FR3 H94 P64 7X8 |
DOI | 10.1111/fcp.12704 |
DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed Bacteriology Abstracts (Microbiology B) Biotechnology Research Abstracts Industrial and Applied Microbiology Abstracts (Microbiology A) Toxicology Abstracts Virology and AIDS Abstracts Technology Research Database Environmental Sciences and Pollution Management Engineering Research Database AIDS and Cancer Research Abstracts Biotechnology and BioEngineering Abstracts MEDLINE - Academic |
DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Virology and AIDS Abstracts Biotechnology Research Abstracts Technology Research Database Toxicology Abstracts Bacteriology Abstracts (Microbiology B) AIDS and Cancer Research Abstracts Engineering Research Database Industrial and Applied Microbiology Abstracts (Microbiology A) Biotechnology and BioEngineering Abstracts Environmental Sciences and Pollution Management MEDLINE - Academic |
DatabaseTitleList | MEDLINE - Academic Virology and AIDS Abstracts CrossRef MEDLINE |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Pharmacy, Therapeutics, & Pharmacology |
EISSN | 1472-8206 |
EndPage | 198 |
ExternalDocumentID | 34050969 10_1111_fcp_12704 FCP12704 |
Genre | article Journal Article |
GeographicLocations | Austria China |
GeographicLocations_xml | – name: Austria – name: China |
GroupedDBID | --- --K .3N .GA .GJ .Y3 05W 0R~ 10A 1B1 1OB 1OC 29H 31~ 33P 36B 3SF 4.4 50Y 50Z 51W 51X 52M 52N 52O 52P 52R 52S 52T 52U 52V 52W 52X 53G 5GY 5HH 5LA 5VS 66C 702 7PT 8-0 8-1 8-3 8-4 8-5 8UM 930 A01 A03 AAESR AAEVG AAHHS AAHQN AAIPD AAMNL AANHP AANLZ AAONW AASGY AAXRX AAYCA AAZKR ABCQN ABCUV ABDBF ABEML ABJNI ABPVW ABQWH ABXGK ACAHQ ACBWZ ACCFJ ACCZN ACGFS ACGOF ACIWK ACMXC ACPOU ACPRK ACRPL ACSCC ACUHS ACXBN ACXQS ACYXJ ADBBV ADBTR ADEOM ADIZJ ADKYN ADMGS ADNMO ADOZA ADXAS ADZMN ADZOD AEEZP AEIGN AEIMD AENEX AEQDE AEUQT AEUYR AFBPY AFEBI AFFPM AFGKR AFPWT AFRAH AFWVQ AFZJQ AHBTC AIACR AITYG AIURR AIWBW AJBDE ALAGY ALMA_UNASSIGNED_HOLDINGS ALUQN ALVPJ AMBMR AMYDB ASPBG ATUGU AVWKF AZBYB AZFZN AZVAB BAFTC BDRZF BFHJK BHBCM BMXJE BROTX BRXPI BY8 C45 CAG COF CS3 D-6 D-7 D-E D-F DCZOG DPXWK DR2 DRFUL DRMAN DRSTM DU5 EAD EAP EBC EBD EBS EBX EJD EMB EMK EMOBN EST ESX EX3 F00 F01 F04 F5P FEDTE FUBAC G-S G.N GODZA GWYGA H.X HF~ HGLYW HVGLF HZI HZ~ IHE IX1 J0M K48 KBYEO LATKE LC2 LC3 LEEKS LH4 LITHE LOXES LP6 LP7 LUTES LW6 LYRES MEWTI MK0 MK4 MRFUL MRMAN MRSTM MSFUL MSMAN MSSTM MXFUL MXMAN MXSTM N04 N05 N9A NF~ NQ- O66 O9- OIG OVD P2P P2W P2X P2Z P4B P4D PALCI Q.N Q11 QB0 R.K RIG RIWAO RJQFR ROL RPZ RX1 SAMSI SUPJJ SV3 TEORI TUS UB1 W8V W99 WBKPD WHWMO WIH WIJ WIK WOHZO WOW WQJ WRC WVDHM WXI WXSBR XG1 YCJ YFH ZXP ZZTAW ~IA ~WT AAYXX AEYWJ AGHNM AGQPQ AGYGG CITATION CGR CUY CVF ECM EIF NPM 7QL 7QO 7T7 7U7 7U9 8FD AAMMB AEFGJ AGXDD AIDQK AIDYY C1K FR3 H94 P64 7X8 |
ID | FETCH-LOGICAL-c3534-856e8898e9e86d60f161b038a885e4d47eedead4b61322571650a75be3316c713 |
IEDL.DBID | DR2 |
ISSN | 0767-3981 1472-8206 |
IngestDate | Thu Jul 10 23:06:54 EDT 2025 Sat Jul 26 02:20:24 EDT 2025 Wed Feb 19 02:27:55 EST 2025 Tue Jul 01 03:36:37 EDT 2025 Thu Apr 24 22:56:09 EDT 2025 Wed Jan 22 16:26:24 EST 2025 |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 1 |
Keywords | electroencephalography pharmacokinetic-pharmacodynamic gender mechanomyography bispectral index sex |
Language | English |
License | 2021 Société Française de Pharmacologie et de Thérapeutique. |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c3534-856e8898e9e86d60f161b038a885e4d47eedead4b61322571650a75be3316c713 |
Notes | Funding information Zhaoyang Xiao and Ashraf A. Dahaba have both equally contributed to the study. The study was financed from the National Natural Science Foundation of China (Beijing, People's Republic of China), Grant No: 81471373, and the National Natural Science Foundation of China (Beijing, People's Republic of China), Grant No: 81071052, both grants awarded to Professor Dr. Zhaoyang Xiao. ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 |
ORCID | 0000-0001-8513-3643 |
PMID | 34050969 |
PQID | 2619485860 |
PQPubID | 2045155 |
PageCount | 17 |
ParticipantIDs | proquest_miscellaneous_2534609965 proquest_journals_2619485860 pubmed_primary_34050969 crossref_primary_10_1111_fcp_12704 crossref_citationtrail_10_1111_fcp_12704 wiley_primary_10_1111_fcp_12704_FCP12704 |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | February 2022 2022-02-00 2022-Feb 20220201 |
PublicationDateYYYYMMDD | 2022-02-01 |
PublicationDate_xml | – month: 02 year: 2022 text: February 2022 |
PublicationDecade | 2020 |
PublicationPlace | England |
PublicationPlace_xml | – name: England – name: Hoboken |
PublicationTitle | Fundamental & clinical pharmacology |
PublicationTitleAlternate | Fundam Clin Pharmacol |
PublicationYear | 2022 |
Publisher | Wiley Subscription Services, Inc |
Publisher_xml | – name: Wiley Subscription Services, Inc |
References | 2009; 23 1982; 57 2001; 322 1993; 9 1990; 10 2010; 104 2000; 44 1971; 47 2011; 31 1981; 6 2011; 13 2005; 60 1972; 5 1998; 275 1999; 724 2004; 75 1993; 78 2011; 108 2006; 61 2003; 91 1986; 9 2005; 101 1993; 77 1997; 14 2008; 25 2003; 47 2003; 49 2008; 22 2011; 26 1992; 20 1999; 90 2009; 103 2006; 103 2018; 57 Shi HJ (e_1_2_11_6_1) 2011; 31 e_1_2_11_10_1 e_1_2_11_32_1 e_1_2_11_31_1 e_1_2_11_30_1 e_1_2_11_14_1 e_1_2_11_13_1 e_1_2_11_35_1 Apfelbaum JL (e_1_2_11_8_1) 1993; 77 e_1_2_11_34_1 e_1_2_11_11_1 e_1_2_11_33_1 e_1_2_11_7_1 e_1_2_11_29_1 e_1_2_11_28_1 e_1_2_11_5_1 e_1_2_11_27_1 e_1_2_11_4_1 e_1_2_11_3_1 e_1_2_11_2_1 Chernik DA (e_1_2_11_12_1) 1990; 10 e_1_2_11_21_1 e_1_2_11_20_1 Friis‐Hansen B (e_1_2_11_26_1) 1971; 47 e_1_2_11_25_1 e_1_2_11_24_1 e_1_2_11_9_1 e_1_2_11_23_1 e_1_2_11_22_1 e_1_2_11_18_1 e_1_2_11_17_1 e_1_2_11_16_1 e_1_2_11_15_1 e_1_2_11_19_1 |
References_xml | – volume: 9 start-page: 499 year: 1986 end-page: 502 – volume: 57 start-page: 1539 year: 2018 end-page: 1558 article-title: Clinical pharmacokinetics and pharmacodynamics of propofol publication-title: Clin Pharmacokinet – volume: 47 start-page: 241 year: 2003 end-page: 259 article-title: Gender differences in drug effects: implications for anesthesiologists publication-title: Acta Anaesthesiol Scand – volume: 724 start-page: 117 year: 1999 end-page: 126 article-title: High‐performance liquid chromatographic method for the determination of atracurium and laudanosine in human plasma. Application to pharmacokinetics publication-title: J Chromatogr B Biomed Sci Appl – volume: 90 start-page: 1283 year: 1999 end-page: 1287 article-title: Women emerge from general anesthesia with propofol/alfentanil/nitrous oxide faster than men publication-title: Anesthesiology – volume: 23 start-page: 127 year: 2009 end-page: 135 article-title: Investigation of PK–PD drug–drug interaction between acenocoumarol and amoxicillin plus clavulanic acid publication-title: Fundam Clin Pharmacol – volume: 22 start-page: 575 year: 2008 end-page: 578 article-title: Population approaches in paediatrics publication-title: Fundam Clin Pharmacol – volume: 26 start-page: 279 year: 2011 end-page: 285 article-title: The value of population pharmacokinetics and simulation for postmarketing safety evaluation of dosing guidelines for drugs with a narrow therapeutic index: buflomedil as a case study publication-title: Fundam Clin Pharmacol – volume: 75 start-page: 85 year: 2004 end-page: 94 article-title: Perl‐speaks‐NONMEM (PsN)‐‐a Perl module for NONMEM related programming publication-title: Comput Methods Programs Biomed – volume: 9 start-page: 38 year: 1993 end-page: 44 article-title: The Relaxometer: a complete and comprehensive computer‐controlled neuromuscular transmission measurement system developed for clinical research on muscle relaxants publication-title: J Clin Monit – volume: 47 start-page: 264+ issue: Suppl 2 year: 1971 article-title: Body composition during growth. In vivo measurements and biochemical data correlated to differential anatomical growth publication-title: Paediatrics – volume: 108 start-page: 602 year: 2011 end-page: 606 article-title: Effect of sugammadex or neostigmine neuromuscular block reversal on bispectral index monitoring of propofol/remifentanil anaesthesia publication-title: Br J Anaesth – volume: 103 start-page: 26 year: 2009 end-page: 37 article-title: Pharmacokinetic models for propofol–‐defining and illuminating the devil in the detail publication-title: Br J Anaesth – volume: 13 start-page: 143 year: 2011 end-page: 151 article-title: Prediction‐corrected visual predictive checks for diagnosing nonlinear mixed‐effects models publication-title: AAPS J – volume: 61 start-page: 330 year: 2006 end-page: 334 article-title: Haemodynamic and catecholamine stress responses to the Laryngeal Tube‐Suction Airway and the Proseal Laryngeal Mask Airway publication-title: Anaesthesia – volume: 101 start-page: 377 year: 2005 end-page: 381 article-title: The influence of gender on loss of consciousness with sevoflurane or propofol publication-title: Anesth Analg – volume: 60 start-page: 176 year: 2005 end-page: 182 article-title: Kidneys contribute to the extrahepatic clearance of propofol in humans, but not lungs and brain publication-title: Br J Clin Pharmacol – volume: 31 start-page: 1287 year: 2011 end-page: 1289 article-title: Impact of gender on the dose‐effect relationship of cisatracurium publication-title: Nan Fang Yi Ke Da Xue Xue Bao – volume: 57 start-page: 309 year: 1982 end-page: 310 article-title: Potency determination for vecuronium (ORG NC45): comparison of cumulative and single‐dose techniques publication-title: Anesthesiology – volume: 104 start-page: 563 year: 2010 end-page: 576 article-title: Effectiveness, safety, and pharmacokinetic and pharmacodynamic characteristics of microemulsion propofol in patients undergoing elective surgery under total intravenous anaesthesia publication-title: Br J Anaesth – volume: 6 start-page: 429 year: 1981 end-page: 453 article-title: Understanding the dose‐effect relationship: clinical application of pharmacokinetic‐pharmacodynamic models publication-title: Clin Pharmacokinet – volume: 77 start-page: S10 year: 1993 end-page: S14 article-title: The initial clinical experience of 1819 physicians in maintaining anesthesia with propofol: characteristics associated with prolonged time to awakening publication-title: Anesth Analg – volume: 44 start-page: 1138 year: 2000 end-page: 1144 article-title: Bispectral index, predicted and measured drug levels of target‐controlled infusions of remifentanil and propofol during laparoscopic cholecystectomy and emergence publication-title: Acta Anaesthesiol Scand – volume: 49 start-page: 7 year: 2003 end-page: 18 article-title: The STARD statement for reporting studies of diagnostic accuracy: explanation and elaboration publication-title: Clin Chemy – volume: 10 start-page: 244 year: 1990 end-page: 251 article-title: Validity and reliability of the Observer’s Assessment of Alertness/Sedation Scale: study with intravenous midazolam publication-title: J Clin Psychopharmacol – volume: 91 start-page: 773 year: 2003 end-page: 780 article-title: Bispectral index, serum drug concentrations and emergence associated with individually adjusted target‐controlled infusions of remifentanil and propofol for laparoscopic surgery publication-title: Br J Anaesth – volume: 25 start-page: 589 year: 2008 end-page: 595 article-title: Influence of gender on the course of neuromuscular block following a single bolus dose of cisatracurium or rocuronium publication-title: Eur J Anesthesiol – volume: 20 start-page: 511 year: 1992 end-page: 528 article-title: Building population pharmacokinetic–‐pharmacodynamic models. I. Models for covariate effects publication-title: J of Pharmacokinet Biopharm – volume: 322 start-page: 710 year: 2001 end-page: 711 article-title: Sex differences in speed of emergence and quality of recovery after anaesthesia: cohort study publication-title: BMJ – volume: 275 start-page: 1909 year: 1998 end-page: 1920 article-title: Gender differences in autonomic functions associated with blood pressure regulation publication-title: Am J Physiol – volume: 5 start-page: 411 year: 1972 end-page: 459 article-title: Modelling of individual pharmacokinetics for computer‐aided drug dosage publication-title: Comput Biomed Res – volume: 78 start-page: 657 year: 1993 end-page: 665 article-title: Propofol infusion for maintenance of anesthesia in morbidly obese patients receiving nitrous oxide publication-title: Anesthesiology – volume: 103 start-page: 378 year: 2006 end-page: 384 article-title: Bispectral‐index‐guided versus clinically guided remifentanil/propofol analgesia/sedation for interventional radiological procedures: an observer‐blinded randomized study publication-title: Anesth Analg – volume: 14 start-page: 91 year: 1997 end-page: 97 article-title: Prospective use of population pharmacokinetics/pharmacodynamics in the development of cisatracurium publication-title: Pharm Res – ident: e_1_2_11_23_1 doi: 10.1093/bja/aeq040 – ident: e_1_2_11_4_1 doi: 10.1017/S026502150800402X – volume: 10 start-page: 244 year: 1990 ident: e_1_2_11_12_1 article-title: Validity and reliability of the Observer’s Assessment of Alertness/Sedation Scale: study with intravenous midazolam publication-title: J Clin Psychopharmacol – ident: e_1_2_11_14_1 doi: 10.1007/BF01627635 – ident: e_1_2_11_21_1 doi: 10.1213/01.ANE.0000154534.71371.4F – ident: e_1_2_11_28_1 doi: 10.2165/00003088-198106060-00002 – ident: e_1_2_11_3_1 doi: 10.1034/j.1399-6576.2003.00036.x – volume: 77 start-page: S10 year: 1993 ident: e_1_2_11_8_1 article-title: The initial clinical experience of 1819 physicians in maintaining anesthesia with propofol: characteristics associated with prolonged time to awakening publication-title: Anesth Analg – ident: e_1_2_11_7_1 doi: 10.1097/00000542-199905000-00010 – ident: e_1_2_11_11_1 doi: 10.1093/bja/aer495 – ident: e_1_2_11_32_1 doi: 10.1097/00000542-199304000-00008 – ident: e_1_2_11_30_1 doi: 10.1111/j.1472-8206.2008.00642.x – ident: e_1_2_11_33_1 doi: 10.1152/ajpregu.1998.275.6.R1909 – ident: e_1_2_11_9_1 doi: 10.1136/bmj.322.7288.710 – ident: e_1_2_11_17_1 doi: 10.1007/s40262-018-0672-3 – volume: 47 start-page: 264+ issue: 2 year: 1971 ident: e_1_2_11_26_1 article-title: Body composition during growth. In vivo measurements and biochemical data correlated to differential anatomical growth publication-title: Paediatrics – ident: e_1_2_11_2_1 doi: 10.1016/0166-2236(86)90158-X – ident: e_1_2_11_24_1 doi: 10.1034/j.1399-6576.2000.440918.x – ident: e_1_2_11_29_1 doi: 10.1111/j.1472-8206.2008.00647.x – ident: e_1_2_11_25_1 doi: 10.1093/bja/aeg258 – ident: e_1_2_11_15_1 doi: 10.1111/j.1365-2044.2006.04548.x – ident: e_1_2_11_27_1 doi: 10.1016/0010-4809(72)90051-1 – ident: e_1_2_11_20_1 doi: 10.1208/s12248-011-9255-z – ident: e_1_2_11_22_1 doi: 10.1097/00000542-198210000-00012 – ident: e_1_2_11_31_1 doi: 10.1111/j.1472-8206.2011.01000.x – ident: e_1_2_11_16_1 doi: 10.1016/S0378-4347(98)00576-3 – ident: e_1_2_11_13_1 doi: 10.1213/01.ane.0000223681.77120.ca – ident: e_1_2_11_5_1 doi: 10.1023/A:1012015719694 – ident: e_1_2_11_19_1 doi: 10.1016/j.cmpb.2003.11.003 – volume: 31 start-page: 1287 year: 2011 ident: e_1_2_11_6_1 article-title: Impact of gender on the dose‐effect relationship of cisatracurium publication-title: Nan Fang Yi Ke Da Xue Xue Bao – ident: e_1_2_11_34_1 doi: 10.1111/j.1365-2125.2005.02393.x – ident: e_1_2_11_18_1 doi: 10.1007/BF01061469 – ident: e_1_2_11_10_1 doi: 10.1373/49.1.7 – ident: e_1_2_11_35_1 doi: 10.1093/bja/aep143 |
SSID | ssj0017016 |
Score | 2.3382313 |
Snippet | A quick literature search using “sex/gender” vs. the commonly used hypnotic propofol or neuromuscular‐blocking agent cisatracurium will reveal numerous... A quick literature search using "sex/gender" vs. the commonly used hypnotic propofol or neuromuscular-blocking agent cisatracurium will reveal numerous... |
SourceID | proquest pubmed crossref wiley |
SourceType | Aggregation Database Index Database Enrichment Source Publisher |
StartPage | 182 |
SubjectTerms | Anesthesia Anesthetics, Intravenous Atracurium - analogs & derivatives Austria bispectral index electroencephalography Ethnic factors Female Gender Gender aspects Gender differences Geographical locations Humans Lag time Male mechanomyography Men Parameters Pharmacodynamics Pharmacokinetics pharmacokinetic‐pharmacodynamic Pharmacology Propofol sex Sex Characteristics Sex differences Transgender Persons Weight White people Women |
Title | Location matters: Overlooked ethnic‐geographic effect in China and Austria on propofol/cisatracurium sex differences among a population pharmacokinetic/pharmacodynamic (PopPK/PD) covariate analysis in men, women, and one transgender subject |
URI | https://onlinelibrary.wiley.com/doi/abs/10.1111%2Ffcp.12704 https://www.ncbi.nlm.nih.gov/pubmed/34050969 https://www.proquest.com/docview/2619485860 https://www.proquest.com/docview/2534609965 |
Volume | 36 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3bbtNAEF1VfeoLl3ILFDQgVBUpTtx4d7OGp6oQVVwt1Ep9QLJ8WbdRE9uqbUR44hP4Rj6BL2Bm13YpFwnxlijrzNjemZ3ZmT2HsceSSjmp4g4uVVOHZ6nrxCJWDk99TD7QZaYxbQ28eSsPjvjLY3G8xp51Z2EsPkS_4UaWYfw1GXgUVz8ZeZaUIyqbEhYo9WpRQPS-h44imHFTp5yiI_B8tduiClEXT3_l5bXotwDzcrxqFpzZVfahU9X2mZyNmjoeJZ9_QXH8z3u5xq60gSjs2Zlzna3pfJNtBxbJejWEw4uDWdUQtiG4wLhe3WDfXxd2rw-WFqDzKbxDo1gQgGcKuj7N58m3L19PLMX66TwB2zgC8xwMZTdEeQp7ljUE8G9KYmvIisU4of6i84iqAM0SKv0JOg4X9GhguJEggrLnHYOyVewMnwIqO-6-p6s8WqLgnaAog1fj4PkTSIqPEcqrNUq3WCykz1LnQzBIFEOjVZFrqGkJPzE0e1A1MW1W3WRHsxeH-wdOSx_hJJ7wuKOE1Er5SvtayVS6GQa3seupSCmhecqnGB6gHfFYUkYuMHEUbjQVsfa8XZlg8n6Lreco8g6DbDJJs0hrLWTG0cdjVCWzhLJP5bnZRA3YTjeRwqTFVieKj0XY5Vj4hkPzhgfsUT-0tIAifxq01c3GsPUpVUi5LldCSXfAHvY_ozegEk-U66LBMXjjEoN-KQbstp3FvRSPG6wfH5U1c_Hv4sPZfmA-3P33offYxoROhpiG9i22Xp83-j7Ga3X8wBjmD0y3QOo |
linkProvider | Wiley-Blackwell |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3bbtNAEF2V8gAv3C-BAgNCVZHixI13NxvES9USBZoWC7VSX5Dly7qNmthW4yDCE5_AN_IJfAEzu7ZLuUiIt0RZZ8b2zOzM7uw5jD2XtJWTKO7gVNV3eJq4TiQi5fBkgMUHhswkoqWBvX05OuRvj8TRCntVn4Wx-BDNght5honX5OC0IP2Tl6dx0aF9U36JXSZGb3LLnfcNeBQBjZudyj6GAm-gNitcIerjaS69OBv9lmJezFjNlDO8zj7UytpOk9POoow68edfcBz_925usGtVLgpb1nhushWd3WLrvgWzXrbh4Pxs1rwN6-Cfw1wvb7Pv49wu98HMYnS-hHfoF1PC8ExAlyfZJP725euxZVk_mcRge0dgkoFh7YYwS2DLEocA_k1BhA1pPu3G1GJ0FtJGwGIGc_0JahoXDGpg6JEghKKhHoOiUuwUHwMq262_J8ssnKHgDT8v_N2uv_MC4vxjiPJKjdItHAvpM9NZGwwYRdtolWcaSprFjw3THswXEa1X3WGHw9cH2yOnYpBwYk943FFCaqUGSg-0kol0U8xvI9dToVJC84T3MUNAV-KRpKJcYO0o3LAvIu15mzLG-v0uW81Q5H0Gaa-XpKHWWsiUY5jHxEqmMRWgynPTnmqxjdqSgriCVyeWj2lQl1n4hgPzhlvsWTO0sJgifxq0VptjUIWVeUDlLldCSbfFnjY_Y0CgXZ4w0_kCx-CNS8z7pWixe9aMGykeN3A_A1TWGOPfxQfDbd98ePDvQ5-wK6ODvXEwfrO_-5Bd7dFBEdPfvsZWy7OFfoTpWxk9Nl76AxfkRQM |
linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1fb9MwELfGkBAv4z90DDgQmobUtFljuw48TSvVYGNEaJP2MClKYmer1ibRmiDKEx-Bz8hH4BNwtpOM8UdCvLWqm7skvvOd7_z7EfKc61KOFNTBpWro0FS6Tsxi4VDpY_KBLlPGemvg3T7fOaRvj9jREnnVnIWx-BDthpu2DOOvtYEXMv3JyNOk6OmyKb1CruJVhc68Rh9a7CiNM24KlUP0BJ4vNmtYId3G0_718mL0W4R5OWA1K874BjludLWNJme9qox7yedfYBz_82ZukpU6EoUtO3VukSWV3SbrgYWyXnTh4OJk1rwL6xBcgFwv7pDve7nd7IOZReh8Ce_RKqYawVOCKk-zSfLty9cTy7F-OknAdo7AJAPD2Q1RJmHL0oYAXqbQdA1pPu0nusHoPNJlgGoGc_UJGhIXdGlgyJEggqIlHoOiVuwMnwIq22--y0UWzVDwRpAXwW4_GL2AJP8YobxSoXQLxqL1mamsCwaKomu0yjMFpV7DTwzPHsyrWO9W3SWH49cH2ztOzR_hJB7zqCMYV0L4QvlKcMndFKPb2PVEJARTVNIhxgdoSDTmOiVnmDkyNxqyWHneJk8we79HljMU-YBAOhjINFJKMZ5SdPIYVvE00emn8Nx0IDpko5lIYVKDq2uOj2nYJFn4hkPzhjvkWTu0sIgifxq01szGsHYq81Anu1Qwwd0Oedr-jO5A13iiTOUVjsEb5xj1c9Yh9-0sbqV41ID9-KismYt_Fx-OtwPzYfXfhz4h14LRONx7s7_7kFwf6FMiprl9jSyX55V6hLFbGT82NvoDRIRDuw |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Location+matters%3A+Overlooked+ethnic-geographic+effect+in+China+and+Austria+on+propofol%2Fcisatracurium+sex+differences+among+a+population+pharmacokinetic%2Fpharmacodynamic+%28PopPK%2FPD%29+covariate+analysis+in+men%2C+women%2C+and+one+transgender+subject&rft.jtitle=Fundamental+%26+clinical+pharmacology&rft.au=Dahaba%2C+Ashraf+A&rft.au=Xiao%2C+Zhaoyang&rft.au=Zhu%2C+Xiaoling&rft.au=Oettl%2C+Karl&rft.date=2022-02-01&rft.eissn=1472-8206&rft.volume=36&rft.issue=1&rft.spage=182&rft_id=info:doi/10.1111%2Ffcp.12704&rft_id=info%3Apmid%2F34050969&rft.externalDocID=34050969 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0767-3981&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0767-3981&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0767-3981&client=summon |